Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

New Biologic Drugs for Ulcerative Colitis

“…The heterodimer formed is cleaved by ubiquitous ribonuclease H, resulting in a reduction in ICAM-1 protein expression (44). Initial positive results in CD patients reported in a pilot study were not confirmed in two subsequent placebo controlled trial (45)(46)(47). Instead in a placebo controlled trial with ISIS 2302 in enema formulation showed significant improvement in 40 patients with distal UC (48).…”

Novel Drug Therapies for the Treatment of Crohn's Disease

“…administered ISIS 2302 [43]. Only 2 of 60 (3.3%) ISIS-2302-treated and none of placebo treated patients reached the primary endpoint; steroid free remission at week 14.…”

Current and Future Biological Treatments in Inflammatory Bowel Disease

“…A pilot trial in patients with moderate CD (including 15 patients treated with 13 intravenous infusions of 0.5, 1.0 or 2.0 mg/kg ISIS 2302 vs 5 patients with placebo over 26 day) demonstrated a higher remission rate in ISIS 2302-treated group compared with the placebotreated group on day 33 (47% vs 20%) [27,28]. Another larger randomized placebocontrolled trial also failed to show any benefit of ISIS 2302 for active CD [29].…”